Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 1911-1919

  Carter, Joseph J ^a   Koutsky, Laura A ^b   Hughes, James P ^b   Lee, Shu Kuang ^b   Kuypers, Jane ^b   Kiviat, Nancy ^b   Galloway, Denise A ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY RESPONSE; ARTICLE; FEMALE; FEMALE GENITAL TRACT INFECTION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SEROCONVERSION; STRAIN DIFFERENCE; VIRUS CAPSID; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 0034085544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315498     Document Type: Article

References (30)

1. 1. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst Monogr 1998;23:27-30.
2. 2. International Agency for Research on Cancer (IARC) monographs on the evaluation of the carcinogenic risks to humans, vol. 64, Human papillomaviruses. Lyon, France: IARC, 1995.
3. 3. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
4. 4. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-91.
5. 5. Carter JJ, Galloway DA. Humoral immune response to human papillomavirus infection. Clin Dermatol 1997;15:249-59.
6. 6. Gissmann L. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am 1996;23:625-39.
7. 7. Kirnbauer, R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996;39:54-61.
8. 8. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
9. 9. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-36.
10. 10. Dillner J, Wiklund F, Lenner P, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 1995;60:377-82.
11. 11. Wikstrom A, Eklund C, Von Krogh G, Lidbrink P, Dillner J. Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas. APMIS 1997;105:884-8.
12. 12. Eisemann C, Fisher SG, Gross G, Muller M, Gissmann L. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J Gen Virol 1996;77:1799-803.
13. 13. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type-16. J Natl Cancer Inst 1994;86:494-9.
14. 14. Carter JJ, Wipf GC, Hagensee ME, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-18.
15. 15. Af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998;177: 1710-4.
16. 16. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997;6:233-7.
17. 17. van Doornum G, Prins M, Andersson-Ellstrom A, Dillner J. Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect 1998;74:354-60.
18. 18. Andersson-Ellstrom A, Dillner J, Hagmar B, et al. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-8.
19. 19. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22.
20. 20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. 21. Breslow NE, Day NE. Statistical methods in cancer research. Vol 2. The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
22. 22. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:630-8.
23. 23. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172: 1425-30.
24. 24. Wikstrom A, van Doornum GJ, Kirnbauer R, Quint WG, Dillner J. Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol 1995;46:368-74.
25. 25. Cheng G, Icenogle JP, Kirnbauer R, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995;172: 1584-7.
26. 26. Ellis JR, Etherington I, Galloway D, Luesley D, Young LS. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16 [letter]. Lancet 1997;349: 1069-70.
27. 27. Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:796-802.
28. 28. Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia, II: systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999;80: 409-17.
29. 29. Elfgren K, Bistoletti P, Dillner L, Walboomers JM, Meijer CJ, Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 1996;174:937-42.
30. 30. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.